Posts

BMS Breaks Clinical Losing Streak with Positive Phase 3 Myeloma Readout for Iberdomide

on

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

on

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

on

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

on

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

on

Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

on

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

on

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

on

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag's Adjuvant Melanoma Setback at ASCO 2025

on

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

on

Bristol Myers CEO: America's Biopharma Leadership Not Guaranteed

on

'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

on

Over 500 BMS jobs axed in latest round of NJ cuts

on

BMS to close Illinois site as part of cell therapy manufacturing consolidation

on

Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial

on

Bristol Myers Squibb's Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

on

Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey

on

Bristol Myers Squibb Expands Cost-Cutting Measures and Streamlines Pipeline for Future Growth

on

Pharmaceutical Giants Bristol Myers Squibb and Kyowa Kirin Announce 119 Layoffs in New Jersey Amid Restructuring Efforts

on